Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$34.38

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $34.38 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $34.38 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $34.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $34.3811/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145965516 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $384.50 12/31/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314671
Principal investigator 1 Allergan, Inc. $2,451.07 12/31/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721316937
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $60.00 12/31/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 748986777
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $19,772.35 12/31/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 748986835
Principal investigator 1 Amgen Inc. $302.62 12/29/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888353
Principal investigator 1 Amgen Inc. $2,880.00 12/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 753888083
Principal investigator 1 Amgen Inc. $1,800.00 12/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 753888499
Principal investigator 1 Amgen Inc. $95.00 12/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 753889393
Principal investigator 1 Allergan, Inc. $4,558.10 12/23/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721313933
Principal investigator 1 H. Lundbeck A S $2,249.98 12/14/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612873
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,150.00 12/11/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 748986523
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,033.53 12/11/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 748986539
Principal investigator 1 Amgen Inc. $1,569.04 12/10/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 753887405
Principal investigator 1 Biogen, Inc. $6,001.00 12/10/2020 Non-covered Recipient Entity
Michigan Headache And Neurological Institute PC
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia No dispute reported 06/30/2026 736754437
Principal investigator 1 Amgen Inc. $1,210.48 12/07/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 753888075
Principal investigator 1 H. Lundbeck A S $182.25 12/07/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612829
Principal investigator 1 H. Lundbeck A S $16,862.29 12/07/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612831
Principal investigator 1 H. Lundbeck A S $1,023.30 12/07/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612833
Principal investigator 1 Amgen Inc. $605.24 12/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888331
Principal investigator 1 Amgen Inc. $302.62 12/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 753888489
Principal investigator 1 Amgen Inc. $302.62 12/01/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888315
Principal investigator 1 Allergan, Inc. $7,500.25 11/23/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721309611
Principal investigator 1 Amgen Inc. $605.24 11/22/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 753888479
Principal investigator 1 H. Lundbeck A S $7,500.00 11/19/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period No dispute reported 06/30/2026 747612705
Principal investigator 1 Amgen Inc. $605.24 11/17/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888303
Principal investigator 1 Amgen Inc. $302.62 11/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888291
Principal investigator 1 Amgen Inc. $4,707.12 10/27/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 753887397
Principal investigator 1 Amgen Inc. $605.24 10/25/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 753888459
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721304293
Principal investigator 1 Amgen Inc. $605.24 10/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888281
Principal investigator 1 Amgen Inc. $302.62 10/06/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 753888267
Principal investigator 1 Allergan, Inc. $10,000.00 10/01/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721301405
Principal investigator 1 H. Lundbeck A S $2,000.00 09/21/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747612473
Principal investigator 1 Amgen Inc. $7,000.00 09/19/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 731628403
Principal investigator 1 Allergan, Inc. $169.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721294909
Principal investigator 1 Allergan, Inc. $4,315.45 08/12/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721289625
Principal investigator 1 H. Lundbeck A S $500.00 08/10/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747612253
Principal investigator 1 H. Lundbeck A S $6,733.14 08/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747612239
Principal investigator 1 H. Lundbeck A S $216.00 08/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747612241
Principal investigator 1 H. Lundbeck A S $1,981.46 07/20/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612077
Principal investigator 1 Allergan, Inc. $5,920.95 07/14/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721283723
Principal investigator 1 Allergan, Inc. $1,000.00 07/06/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721282593
Principal investigator 1 H. Lundbeck A S $7,500.00 07/06/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 747612015
Principal investigator 1 H. Lundbeck A S $39,310.56 06/29/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG. INSTITUTE
Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) No dispute reported 06/30/2026 747611957
Principal investigator 1 H. Lundbeck A S $2,932.90 06/29/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611961
Principal investigator 1 H. Lundbeck A S $2,132.16 06/29/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611963
Principal investigator 1 H. Lundbeck A S $2,816.48 06/22/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611817
Principal investigator 1 H. Lundbeck A S $6,625.40 05/26/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611593
Principal investigator 1 Allergan, Inc. $600.00 05/22/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721276655
Principal investigator 1 H. Lundbeck A S $500.00 05/18/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611527
Principal investigator 1 Allergan, Inc. $1,163.75 05/14/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721275219
Principal investigator 1 Amgen Inc. $2,878.06 05/05/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 731640405
Principal investigator 1 H. Lundbeck A S $135.00 04/27/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611405
Principal investigator 1 H. Lundbeck A S $2,038.14 04/27/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611407
Principal investigator 1 H. Lundbeck A S $20,804.10 04/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611333
Principal investigator 1 Allergan, Inc. $3,206.25 04/14/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721269803
Principal investigator 1 Eli Lilly and Company $939.60 04/09/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728748879
Principal investigator 1 Amgen Inc. $763.83 04/08/2020 Non-covered Recipient Entity
MICHIGAN HEAD NEURO INSTI
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 731635777
Principal investigator 1 Amgen Inc. $529.30 04/08/2020 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST.
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 731638897
Principal investigator 1 Amgen Inc. $639.64 04/08/2020 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 731641199
Principal investigator 1 H. Lundbeck A S $1,056.38 04/06/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611297
Principal investigator 1 H. Lundbeck A S $270.00 04/06/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611299
Principal investigator 1 Eli Lilly and Company $2,911.00 03/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 728736915
Principal investigator 1 H. Lundbeck A S $21,074.53 03/23/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG. INSTITUTE
Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) No dispute reported 06/30/2026 747611153
Principal investigator 1 H. Lundbeck A S $21,074.53 03/23/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG. INSTITUTE
Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) No dispute reported 06/30/2026 747611155
Principal investigator 1 H. Lundbeck A S $768.76 03/23/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611157
Principal investigator 1 Amgen Inc. $15,194.00 03/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 731635783
Principal investigator 1 Amgen Inc. $21,371.84 03/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 731638885
Principal investigator 1 Amgen Inc. $18,135.19 03/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 731641191
Principal investigator 1 Amgen Inc. $14,070.00 03/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 731646135
Principal investigator 1 Allergan, Inc. $6,005.90 03/16/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721264103
Principal investigator 1 H. Lundbeck A S $135.00 03/16/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611065
Principal investigator 1 H. Lundbeck A S $1,144.25 03/16/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747611067
Principal investigator 1 Amgen Inc. $2,963.11 03/13/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 731628409
Principal investigator 1 Amgen Inc. $103.50 03/09/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 731646131
Principal investigator 1 H. Lundbeck A S $6,108.56 02/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747610845
Principal investigator 1 Amgen Inc. $20,739.00 02/22/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Work Productivity Study No dispute reported 06/30/2026 731646127
Principal investigator 1 H. Lundbeck A S $222.75 02/18/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747610753
Principal investigator 1 Allergan, Inc. $9,455.35 02/14/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721257215
Principal investigator 1 Amgen Inc. $28,951.00 01/30/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 731635771
Principal investigator 1 Amgen Inc. $36,964.00 01/30/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 731638873
Principal investigator 1 Amgen Inc. $14,032.00 01/30/2020 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 731641179
Principal investigator 1 H. Lundbeck A S $4,595.21 01/27/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747610613
Principal investigator 1 Allergan, Inc. $2,000.00 01/24/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721250671
Principal investigator 1 Amgen Inc. $16,493.66 01/20/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 731646139
Principal investigator 1 Eli Lilly and Company $150.00 01/17/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 728738797
Principal investigator 1 Amgen Inc. $45,791.90 01/16/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 731638891
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721246203
Principal investigator 1 Allergan, Inc. $11,350.60 01/14/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721247293
Principal investigator 1 Amgen Inc. $29,415.83 01/09/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 731635786
Principal investigator 1 Amgen Inc. $1,627.51 01/09/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 731638879
Principal investigator 1 Amgen Inc. $1,548.40 01/09/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 731641185
Principal investigator 1 Amgen Inc. $28,401.93 01/07/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 731641196
Principal investigator 1 H. Lundbeck A S $8,100.00 01/03/2020 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 747610481
Principal investigator 1 Amgen Inc. $747.69 01/01/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 731640411
Principal investigator 1 Novartis Pharmaceuticals Corporation $105,486.71 01/01/2020 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A 12 MONTHS PROSPECTIVE, INTERVENTIONAL, MULTINATIONAL, OPEN-LABEL, ACTIVE-CONTROLLED STUDY COMPARING SUSTAINED BENEFIT OF TWO TREATMENT PARADIGMS (ERENUMAB 140 MG QM VS ORAL PROPHYLACTICS) No dispute reported 06/30/2026 721493495